一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
肿瘤细胞治疗研究
英文原题:Delivery of a novel membrane-anchored Fc chimera enhances NK cell-mediated killing of tumor cells and persistently virus-infected cells.
Delivery of a novel membrane-anchored Fc chimera enhances NK cell-mediated killing of tumor cells and persistently virus-infected cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
抗体依赖性细胞介导的细胞毒性(ADCC)是NK细胞杀伤癌细胞或病毒感染细胞最强大的机制之一。研究人员创建了一种新型嵌合蛋白(NA-Fc),其在细胞中表达时,可将IgG Fc结构域定位在质膜上,模拟IgG结合于细胞表面的方向。该NA-Fc嵌合体与PM21-NK细胞进行了测试,PM21-NK细胞通过先前开发的基于颗粒的方法产生,该方法可产生用于免疫治疗应用的优质NK细胞。实时活力检测显示,PM21-NK对表达NA-Fc的卵巢癌和肺癌细胞的杀伤作用更强,这与NK细胞释放TNF-和IFN-细胞因子增加相关,并依赖于CD16-Fc相互作用。慢病毒将NA-Fc递送至靶细胞后,提高了PM21-NK细胞对A549和H1299肺癌、SKOV3卵巢癌及A375黑色素瘤细胞的杀伤速率。这种NA-Fc导向的杀伤作用也扩展至病毒感染细胞,将NA-Fc递送至持续感染副流感病毒的肺细胞后,PM21-NK细胞的杀伤作用增强。与其对PM21-NK细胞的作用相反,NA-Fc分子并未增强补体介导的肺癌细胞裂解。
我们的研究为这种新型NA-Fc嵌合体的应用奠定了基础,该嵌合体可在溶瘤病毒治疗期间特异性递送至肿瘤,通过与过继性NK细胞联合治疗来标记靶细胞以供ADCC杀伤。这一策略可能消除为开发新型抗体治疗药物而寻找独特癌症特异性抗原的需要。
Antibody-dependent cellular cytotoxicity (ADCC) is one of the most powerful mechanisms for Natural Killer (NK) cells to kill cancer cells or virus-infected cells. A novel chimeric protein (NA-Fc) was created, which when expressed in cells, positions an IgG Fc domain on the plasma membrane, mimicking the orientation of IgG bound to the cell surface. This NA-Fc chimera was tested with PM21-NK cells, produced through a previously developed particle-based method which yields superior NK cells for immunotherapeutic applications.
Real time viability assays revealed higher PM21-NK killing of both ovarian and lung cancer cells expressing NA-Fc, which correlated with increased release of TNF- and IFN- cytokines from NK cells and was dependent on CD16-Fc interactions. Lentivirus delivery of NA-Fc to target cells increased the rate of PM21-NK cell killing of A549 and H1299 lung, SKOV3 ovarian and A375 melanoma cancer cells.
This NA-Fc-directed killing was extended to virus infected cells, where delivery of NA-Fc to lung cells that were persistently infected with Parainfluenza virus resulted in increased killing by PM21-NK cells. In contrast to its effect on PM21-NK cells, the NA-Fc molecule did not enhance complement mediated lysis of lung cancer cells.
Our study lays the foundation for application of the novel NA-Fc chimera that could be delivered specifically to tumors during oncolytic virotherapy to mark target cells for ADCC by co-treatment with adoptive NK cells. This strategy would potentially eliminate the need to search for unique cancer specific antigens for development of new antibody therapeutics.
MEMBER ACCOUNT
登录成功会直接打开下一页。